Wells Fargo’s Context Therapeutics CNTX Stock Holding History
Bought
Maintained
Sold
Other funds holding CNTX
Wells Fargo's CNTX Position: Q3 2026 in Review
Wells Fargo reduced its Context Therapeutics (CNTX) stake by 67% in Q3 2026, selling an estimated $28K and leaving 28,312 shares worth $8.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6155.
Wells Fargo first reported a position in CNTX in Q4 2021 and has held it in 12 quarters since. The position peaked at $47.1K in Q2 2026. 87 funds tracked by Wall St. Rank hold CNTX as of Q3 2026.
- Wells Fargo held 28,312 shares of Context Therapeutics worth $8.5K as of Q3 2026.
- Wells Fargo sold 56,669 Context Therapeutics shares in Q3 2026, an estimated $28K.
- Context Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #6155 holding.
- Wells Fargo first reported a position in Context Therapeutics in Q4 2021 and has held it in 12 quarters since.
- Wells Fargo's Context Therapeutics position peaked at $47.1K in Q2 2026.
- 87 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2026.
Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.